brivanib

Ligand id: 5671

Name: brivanib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 84.67
Molecular weight 370.14
XLogP 3.99
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Brivanib progressed to Phase 3 clinical trials for liver and colorectal cancers. Click here to link to ClinicalTrials.gov's complete list of brivanib trials. Treatment with brivanib has been linked to an increased risk of developing fatal adverse events in hepatocellular carcinoma patients in a meta-analysis report [3].
Mechanism Of Action and Pharmacodynamic Effects
Like other angiokinase inhibitors, brivanib's anti-neoplastic effect is due to its suppression of the neo-angiogenesis required for tumour growth and expansion [1].